Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-5565 placebo-controlled safety study in fibromyalgia patients with chronic kidney disease
2014-003972-21Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mirogabalin in fibromyalgia (FM) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Safety and tolerability. Started Jun 2015; status: completed.
02
Drugs
mirogabalin
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on 2014-003972-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003972-21.